New data for Roche’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA) March 16, 2022March 16, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: New three-year data for Roche’s Evrysdi (risdiplam)…Data for Roche’s Evrysdi® (risdiplam) published in…New Roche data for Evrysdi show improved motor…Roche’s Evrysdi (risdiplam) granted FDA priority…Roche’s Evrysdi (risdiplam) granted FDA priority…Positive new data for Roche’s Evrysdi in largest…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
